Category: clinical study retractions

NIH cancer paper retracted for faked data

JCIFollowing an investigation into research misconduct, the Journal of Clinical Investigation has retracted a cancer genetics paper from a laboratory at the National Institutes of Health due to “data falsification and fabrication” of four figures and a table in the paper.

The paper, “FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer,” describes an overexpressed gene in mouse prostate cancers that appears to suppress immune system cells.

The journal retracted the paper following an investigation into author Stephanie K. Watkins, then a postdoctoral fellow at the National Cancer Institute. According to a NIH press release released about the study in March 2011, the work “has led to the submission of a patent application by the NIH on behalf of Hurwitz and Watkins to target FOXO3 as a way to boost immune responses in cancer and to silence excessive immune responses in autoimmune diseases.” We found an NIH record of the patent application, but no record of an approved patent at the United States Patent and Trademark Office under either Hurwitz or Watkins’ names.

The paper has been cited 62 times, according to Thomson Scientific’s Web of Knowledge. Here’s the full notice: Continue reading NIH cancer paper retracted for faked data

CrossFit gym owner sues Ohio State, says fraudulent data led to $273 million in NIH grants

Mitch Potterf
Mitch Potterf
In an lawsuit unsealed yesterday, the owner of a CrossFit gym is suing Ohio State University (OSU) under the False Claims Act, claiming that researchers faked data in a university-based study involving his gym — and that OSU used the study to win $273 million in Federal grants.

The suit, originally filed in February in the U.S. District Court of Southern Ohio by Mitch Potterf, owner of a Columbus, Ohio CrossFit, alleges that a 2013 paper by OSU’s Steven Devor and colleagues falsely reported that nine subjects had dropped out of the study because of “overuse or injury.” The study, we should note, concluded that CrossFit is a useful form of exercise. It has been cited twice, according to Thomson Scientific’s Web of Knowledge.

As John Thomas, an attorney who handles False Claims Act cases, explained in a Retraction Watch guest post in March: Continue reading CrossFit gym owner sues Ohio State, says fraudulent data led to $273 million in NIH grants

Highly cited cancer researcher pulls review for “similar text and illustrations”

AbdomImaging_ak8The author of a 2006 review article published in Abdominal Imaging has retracted it because it hews too closely to previously published articles.

The review described the latest imaging techniques used in cancer, focusing on genitourinary conditions.

Here’s the full text of the retraction notice for “New Horizons in Genitourinary Oncologic Imaging”:

Continue reading Highly cited cancer researcher pulls review for “similar text and illustrations”

Widely covered editorial extolling importance of diet over exercise “temporarily removed”

Source: NIH
Source: NIH

The British Journal of Sports Medicine has “temporarily removed” an editorial arguing that physical activity alone will not cure the obesity epidemic, following an expression of concern.

In its place stands the following message:

This paper has been temporarily removed following an expression of concern.

First author Assem Malhotra, based at the Department of Cardiology, Frimley Park Hospital and Consultant Clinical Associate to the Academy of Medical Royal Colleges, told us the paper was pulled due to a “technical issue,” and an “official explanation” would be forthcoming.

Indeed, just this morning, we received a statement from Fiona Godlee, editor of the British Medical Journal, which publishes the British Journal of Sports Medicine:

Continue reading Widely covered editorial extolling importance of diet over exercise “temporarily removed”

Drug study pulled after researchers admit altering trial protocol

egypt anaesthesiaThe Egyptian Journal of Anaesthesia is retracting a 2014 paper by a pair of researchers at Cairo University who appear to have tinkered with their protocol after having received ethics approval.

The paper, titled “Can Sugammadex improve the reversal profile of Atracurium under Sevoflurane anesthesia?” was written by Heba Ismail Ahmed Nagy and Hany Wafik Elkadi, both in the department of anesthesiology.

Sugammadex, or Bridion, is given to rapidly reverse the effects of drugs that keep patients motionless during surgery. It is available throughout the world but not, as it happens, in the United States, where the Food and Drug Administration has refused to approve the agent because of fears that it might provoke severe allergic-like reactions.

According to the retraction notice:

Continue reading Drug study pulled after researchers admit altering trial protocol

Chinese medical case study erased after guardian consent withdrawn

JMCRThe editor of the Journal of Medical Case Reports, a BioMed Central title, has retracted and removed a case study of a novel surgical treatment after the patient’s legal guardian withdrew consent post-publication.

The paper, “Novel two-stage surgical treatment for Cantrell syndrome complicated by severe pulmonary hypertension: a case report,” describes the treatment of a six-month-old Han Chinese girl suffering from a rare combination of birth defects called Cantrell syndrome, complicated by pulmonary hypertension.

The original article, published in March 2014, has been removed from the journal’s website, though the abstract can be read on PubMed. It is unclear whether the authors, the child’s guardian, or some other party informed the editor of the withdrawal of consent.

The brief notice offers few details:

Continue reading Chinese medical case study erased after guardian consent withdrawn

When should a paper be retracted? A tale from the obesity literature

obesity factsIn our line of work, we see it all — mega-corrections that don’t quite rise to the level of retraction, letters to the editor that point out seemingly fatal flaws in papers that remain untouched, and studies retracted for what seem like minor reasons. It can make you wonder what makes a paper worthy of a retraction. A recent case in an obesity journal may not provide a definitive answer, but it gives us a lot to chew on.

Here’s the story: In September 2013, Rosely Sichieri and a colleague from the State University of Rio de Janeiro submitted an article to Obesity Facts, “Unbalanced Baseline in School-Based Interventions to Prevent Obesity: Adjustment Can Lead to Bias?” The article examined statistical issues in randomized controlled trials of school-based weight loss programs. Peer reviewers said the paper needed major revisions before it could be accepted; the authors revised the paper enough in a second draft, submitted in November 2013, that the original reviewers accepted it. The paper was published in June 2014.

Then, in September 2014, a group of authors including David Allison of the University of Alabama, Birmingham, and colleagues from Clemson, Thomas Jefferson, and the University of Minnesota, wrote a critical letter that was published in the journal in April. The letter, according to a just-published editorial: Continue reading When should a paper be retracted? A tale from the obesity literature

Urology researcher in Iran up to six retractions

safarinejadA urologist in Iran has lost three papers in BJU International, bringing his retraction count to a half-dozen.

In December 2013, we reported on three retractions by Mohammad Reza Safarinejad. None of those notices, about papers related to incontinence and erectile dysfunction, made the reasons for retraction very clear. After that post ran, Safarinejad told us that Hartmut Porst, former president of the European Society for Sexual Medicine, had raised questions about the data in a number of his papers. Porst confirmed that for us earlier this month.

All of the latest papers, about aspects of male sexual dysfunction, are being retracted due to “inappropriate” statistical analyses.

Here’s the notice for “Analysis of association between the 5-HTTLPR and STin2 polymorphisms in the serotonin-transporter gene and clinical response to a selective serotonin reuptake inhibitor (sertraline) in patients with premature ejaculation,” which has been cited 17 times, according to Thomson Scientific’s Web of Knowledge: Continue reading Urology researcher in Iran up to six retractions

Author from China blames translation company for plagiarism in retracted vascular paper

apjcpDo we need a “throwing vendors under the bus” category here at Retraction Watch?

Earlier this year, we reported on the retraction of a paper because of sloppy work by an outside lab. Now, we have the story of a retraction for “negligence” by a translator. Specifically, the author says the passages shared between the retracted 2015 vascular paper and another paper in EMBO Journal are a result of “negligence on the part of the translation company that I trusted to make my manuscript ready for submission.”

Here’s more from the notice in the Asian Pacific Journal of Cancer Prevention, written by Yong Jiang, of Laboratory Medical College, Jilin Medical College, China: Continue reading Author from China blames translation company for plagiarism in retracted vascular paper

Authorship issues spell retraction for breast cancer paper

ijmponcThe corresponding author of a 2014 paper in the Indian Journal of Medical and Paediatric Oncology has retracted the article because he was a bit too generous with his list of coauthors.

The article, “Outcome of neoadjuvant chemotherapy in locally advanced breast cancer: A tertiary care centre experience,” reviewed medical records from a local population of breast cancer patients treated with chemotherapy. It came from a group at the Post Graduate Institute of Medical Education and Research, in Chandigarh. The first author was Tapesh Bhattacharyya, followed by four other names.

According to the notice:  Continue reading Authorship issues spell retraction for breast cancer paper